The objective of the JRC COVID-19 In Vitro Diagnostic Devices and Test Methods Database is to collect in a single place all publicly available information on performance of CE-marked in vitro diagnostic medical devices (IVDs) as well as laboratory-developed devices and related test methods for COVID-19. The database is manually curated and periodically updated.
The database contains publicly available in vitro diagnostic medical devices for COVID-19 and it is being updated periodically. Please note that additional performance (as retrieved from manufacturers web pages) is provided only for devices commercially available with CE-IVD mark.
For more information, please read “ Aim of the website”.
The database contains performance of test methods and devices for COVID-19 diagnostics retrieved from selected scientific articles and it is being updated periodically.
The database provides pre-computed values corresponding to the extent of matchings of the primers and probes from NAAT database methods against high-quality, full length genomic sequences, which are made available by GISAID to enable this analysis.
EUnetHTA - European Network for Health Technology Assessment – developed a COVID-19-related repository of publications and outputs produced jointly or by individual HTA organisations on testing methods and devices for SARS-COV-2.
This section allows surfing in and mining of data and analyses performed on SARS-CoV-2 sequences, like detectability of NAAT amplicons, and the phylodynamics of the pandemic in the European Union countries.
Manufacturers are invited to submit information on new devices not yet listed or to provide performance data not available to the authors at the time of the last update. The submitted information, once verified against the source provider, will be taken into consideration for updating the database.
Manufacturers are invited to submit information and data on rapid antigen tests and lab-based antigenic assays for possible inclusion in the EU common list of COVID-19 antigen tests, ad agreed by HSC. The submitted information, once verified against the source provider, will be forwarded to the HSC Technical Working Group on COVID-19 diagnostic tests for evaluation and review.